Alkaline phosphatase _ ALPL

Price:

623.27 €

Known as:: Alkaline phosphatase _ ALPL
Catalog number:: BM216
Product Quantity:: 0.2 mg
Category:: -
Supplier:: ACR
Gene target:: Alkaline phosphatase _ ALPL

Related genes to: Alkaline phosphatase _ ALPL

Gene:: ALPL ^{NIH gene}
Name:: alkaline phosphatase, biomineralization associated
Previous symbol:: HOPS
Synonyms:: TNSALP, TNALP, TNAP
Chromosome:: 1p36.12
Locus Type:: gene with protein product
Date approved:: 1986-01-01
Date modifiied:: 2018-08-08

Related products to: Alkaline phosphatase _ ALPL

Related articles to: Alkaline phosphatase _ ALPL

Inhibition of mitochondrial complex I by rotenone reduces arterial calcification in vitro.
Cardiovascular diseases are the leading cause of death worldwide, with arterial calcification being a risk factor, especially in patients with diabetes and kidney disease. Arterial calcification involves hydroxyapatite deposition and the transformation of vascular smooth muscle cells (vSMCs) into osteoblast-like cells, processes mediated in part by tissue-nonspecific alkaline phosphatase (TNAP, encoded by ALPL), a key regulator of mineralization. Previous work showed increased activity of electron transport chain complexes I and IV during vSMC calcification. This study examined the role of mitochondrial complex I in vSMC calcification. - Source: PubMed
Publication date: 2026/07/27
Gorgels AndreaKöneke TabeaKarimian SetarehMoellmann JuliaNoels HeidiMarx NikolausGoettsch Claudia
Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats.
To optimize osteoporosis therapy with the parathyroid hormone fragment teriparatide (PTH1-34), we sought to determine whether strontium (Sr) could potentiate the bone anabolic action of intermittent PTH1-34 in ovariectomized rats. Female rats were either Sham-operated or ovariectomized (Ovx) at 6 months of age. Eight weeks after surgery, Ovx rats received either vehicle solutions, 625 mg/kg/day Sr (5 days per week), 8 µg/kg/day PTH1-34 (5 days per week), or the combined treatments for 8 weeks. PTH1-34 reversed Ovx-induced deterioration of trabecular microarchitecture, apparent volumetric bone mineral density (vBMD), and strength, whereas Sr alone increased tissue-level vBMD without significantly affecting trabecular bone mass. Co-treatment with Sr and PTH1-34 further increased trabecular thickness (+ 8.9% vs. PTH1-34 alone), apparent and tissue-level vBMD (+ 9.6% and 6.7% vs. PTH1-34 alone), bone material properties (maximum force, + 18.2% vs. PTH1-34 alone; working energy, + 17% vs. PTH1-34 alone), and trabecular bone strength compared with PTH1-34 alone. In cortical bone, PTH1-34 increased bone volume, cortical thickness, and apparent vBMD, while co-treatment further enhanced cortical thickness (+ 7.2% vs. PTH1-34 alone) and apparent vBMD (+ 7% vs. PTH1-34 alone), maintained the Sr-induced increase in tissue-level vBMD, and significantly improved bone strength. In primary osteoblast cultures, Sr and PTH1-34, administered either alone or in combination, increased Rankl and decreased Opg expression, consistent with the elevated urinary levels of the bone resorption marker deoxypyridinoline in vivo. Sr or PTH1-34 alone stimulated Igf1 and Alpl expression, whereas co-stimulation further enhanced these osteogenic markers. In conclusion, combining Sr with PTH1-34 integrates the osteoanabolic effects of PTH1-34 on bone mass with the mineral-level effects of Sr on bone material properties, leading to synergistic stimulation of bone formation and superior improvements in bone quality and strength. - Source: PubMed
Publication date: 2026/07/28
Thouverey CyrilBadoud IsabelleAmmann Patrick
Seventeen-year follow-up of hypophosphatasia diagnosed in middle-aged siblings harboring a novel intronic and a rare missense ALPL gene mutation.
Hypophosphatasia (HPP) is the rare inborn-error-of-metabolism that features impaired mineralization of the skeleton and teeth due to a deactivating mutation or mutations of the gene ALPL which encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). We report 17-year follow-up of twin sisters and a brother referred in middle-age for painful proximal femoral "stress fractures" and then diagnosed with HPP. They reported generalized muscle and bone pain, metatarsal fractures, arthropathy and, since childhood, tooth loss. Their concordant findings were explained by compound heterozygosity in ALPL for a rare maternal missense mutation (c.1403C > T, p.Ala468Val) in exon 12, together with a novel presumably paternal change (c.863-14G > A) predicting a cryptic mRNA splice site in intron 8. Fractures continued during follow-up until one sister received a three-and-one-half-year course of hydroxyapatite-targeted TNSALP supplementation therapy (asfotase alfa) during which substantial improvement occurred in her clinical, biochemical, and functional parameters as well as quality of life. Following subsequent unplanned treatment cessation she suffered significant clinical deterioration, including new fractures and loss of mobility. Her bone histopathology documented osteomalacia. Treatment resumption restored its benefits. Among ten asymptomatic family members evaluated in this four-generation kindred, eight were carriers heterozygous for either ALPL mutation. Those harboring the maternal missense defect manifested mild hypophosphatasemia, suggesting a dominant-negative mutation effect. This experience underscores the importance of in-depth phenotyping and then clinical follow-up to characterize ALPL variant combinations, and for maintaining effective asfotase alfa treatment. - Source: PubMed
Publication date: 2026/07/28
Conti Francesco GMumm StevenGentile GiovannaLionetto LuanaArgento GiuseppePisarro MorenaPugliese GiuseppeBrandi Maria LuisaWhyte Michael P
Mesenchymal Stem Cells of Epicardial Adipose Tissue Show Differences in Immunophenotype and Osteogenic Potential in Patients with Coronary and Non-Coronary Heart Disease.
Coronary artery calcification (CAC) is a pressing issue in cardiology. Mesenchymal stem cells (MSCs) derived from epicardial adipose tissue (EAT) may serve as a source of osteoblasts in the cardiovascular system. This study aimed to evaluate and compare the immunophenotype, proliferation, and osteogenic potential of EAT-MSCs from patients with coronary artery disease (CAD) and those with aortic stenosis (AS). The immunophenotype of MSCs was analyzed based on key markers: CD105, CD90, CD73, CD31, CD34, CD45, HLA-DR. Cell proliferation was assessed by the doubling time of the population and the specific growth rate of the cultures. The osteogenic potential was evaluated by the expression levels of the , , , and genes using PCR, as well as the protein levels in supernatants via ELISA. Qualitative detection of osteogenic proteins in cells by immunofluorescence staining. The intensity of extracellular matrix mineralization was measured using photometric methods. CD73 expression in EAT-MSCs from CAD patients was nearly 50% lower than in EAT-MSC cultures from AS patients. Following osteogenic induction, EAT-MSCs from CAD patients showed increased expression of osteogenic marker genes and their corresponding proteins. The intensity of extracellular matrix mineralization by osteoblasts derived from EAT-MSCs of CAD patients was higher than in the comparison group. EAT-MSCs from CAD patients with coronary calcification demonstrated reduced CD73 expression in culture and enhanced osteogenic potential compared to patients without coronary artery involvement. - Source: PubMed
Publication date: 2026/07/15
Gruzdeva Olga VSlesareva Tamara AGorbatovskaya Evgeniya EDolmatova Sofia EDyleva Yulia AFanaskova Elena VKokov Alexander NNishonov Asliddin BBarbarash Olga L
Multi-omics analysis reveals the effects of Jinfeng pills on the outcomes of IVF-ET in patients with poor ovarian response: a randomized controlled trial.
Jinfeng pills (JFP), a well-known traditional Chinese medicine (TCM) consisted of 9 herbs, benefit Qi, nourish the blood, effectively regulate the menstrual cycle, promote ovulation and improve endometrial thickness and blood flow. Previous studies have shown that JFP has certain effect on premature ovarian insufficiency (POI). In this prospective cohort study, the effect and mechanisms of JFP on the outcomes of in vitro fertilization and embryo transfer (IVF-ET) in poor ovarian response(POR) was investigated. - Source: PubMed
Publication date: 2026/07/18
Kong XumeiLuo QianwenHuang TianhongChen FuruiZhang YananXiong DongshengQiu YuLai WeiYan XiaoyanLong FangyiGong Yan

Alkaline phosphatase _ ALPL

Related genes to: Alkaline phosphatase _ ALPL

Related products to: Alkaline phosphatase _ ALPL

Related articles to: Alkaline phosphatase _ ALPL

Inhibition of mitochondrial complex I by rotenone reduces arterial calcification in vitro.

Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats.

Seventeen-year follow-up of hypophosphatasia diagnosed in middle-aged siblings harboring a novel intronic and a rare missense ALPL gene mutation.

Mesenchymal Stem Cells of Epicardial Adipose Tissue Show Differences in Immunophenotype and Osteogenic Potential in Patients with Coronary and Non-Coronary Heart Disease.

Multi-omics analysis reveals the effects of Jinfeng pills on the outcomes of IVF-ET in patients with poor ovarian response: a randomized controlled trial.